Medicare Enrolled

Dr. Sunny Patel, MD

Rheumatology · Red Oak, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
106 PLAZA DR, Red Oak, TX 75154
4695526630
In practice since 2013 (12 years)
NPI: 1336583467 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Patel from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Patel? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Patel

Dr. Sunny Patel is a rheumatology in Red Oak, TX, with 12 years in practice. Based on federal Medicare data, Dr. Patel performed 234,227 Medicare services across 941 unique beneficiaries.

Between the years covered by Open Payments, Dr. Patel received a total of $76,139 from 38 pharmaceutical and/or device companies across 912 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Patel is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 12 years in practice▲ Top 3% volume in TX$ $76,139 industry payments

Medicare Practice Summary

Medicare Utilization ↗
234,227
Medicare services
Top 3% in TX for rheumatology
941
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~19,519 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Certolizumab injection (Cimzia)173,200$4$13
Golimumab infusion (Simponi Aria)29,715$10$34
Abatacept infusion (Orencia)19,350$34$104
Infliximab infusion (Remicade)4,740$25$85
Denosumab injection (Prolia/Xgeva)4,620$18$58
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle950$55$189
Administration of chemotherapy into vein, 1 hour or less619$92$345
Office visit, established patient (20-29 min)313$63$184
Injection of additional new drug or substance into vein181$11$85
Office visit, established patient (30-39 min)157$82$270
Injection, methylprednisolone sodium succinate, up to 40 mg120$3$20
Administration of chemotherapy into vein, each additional hour104$21$110
New patient office visit (45-59 min)53$117$415
New patient office visit (30-44 min)43$74$273
Injection, methylprednisolone acetate, 40 mg25$5$30
Drug injection, under skin or into muscle21$10$64
Joint injection, major joint16$57$175
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
23.0% high complexity
76.8% medium
0.2% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$76,139
Total received (2018-2024)
Avg $10,877/year across 7 years
Top 8% in TX for rheumatology
38
Companies
912
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$57,914 (76.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,265 (18.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,960 (5.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$21,729
2023
$21,298
2022
$19,442
2021
$8,038
2020
$2,641
2019
$2,514
2018
$477

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Horizon Therapeutics plc
$35,274
Amgen Inc.
$24,601
UCB, Inc.
$4,290
GlaxoSmithKline, LLC.
$1,875
ABBVIE INC.
$1,390
E.R. Squibb & Sons, L.L.C.
$1,012
PFIZER INC.
$987
Mallinckrodt Hospital Products Inc.
$987
Janssen Biotech, Inc.
$955
AstraZeneca Pharmaceuticals LP
$712
AbbVie, Inc.
$598
ANI Pharmaceuticals, Inc.
$484
AbbVie Inc.
$459
Aurinia Pharma U.S., Inc.
$435
Mallinckrodt Enterprises LLC
$411
Novartis Pharmaceuticals Corporation
$354
GENZYME CORPORATION
$216
Genentech USA, Inc.
$201
Nevro Corp.
$173
Boehringer Ingelheim Pharmaceuticals, Inc.
$100
Lilly USA, LLC
$84
Organon LLC
$63
Fresenius Kabi USA, LLC
$53
Mallinckrodt LLC
$51
Organon Llc
$50
Octapharma USA, Inc.
$50
Ferring Pharmaceuticals Inc.
$40
Exeltis, USA Inc.
$39
HOSPIRA, INC.
$31
Bioventus LLC
$31
Hikma Pharmaceuticals USA
$29
SCILEX PHARMACEUTICALS INC.
$22
DePuy Synthes Sales Inc.
$18
Sandoz Inc.
$15
Merck Sharp & Dohme Corporation
$14
AMAG Pharmaceuticals, Inc.
$13
Ultragenyx Pharmaceutical Inc.
$12
MEDAC PHARMA, INC.
$11
Top 3 companies account for 84.3% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · BENLYSTA · Bimzelx · COSENTYX · Cimzia · Crysvita · DUROLANE · EUFLEXXA · EVENITY · Enbrel · FERAHEME · HUMIRA · HYRIMOZ · Humira · IDACIO · ILARIS · INFLECTRA · KEVZARA · KRYSTEXXA · LUPKYNIS · MONOVISC · Mitigare · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · Otezla · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · Senza · Supartz Fx Sodium Hyaluronate · TALTZ · TAVNEOS · TEPEZZA · TREMFYA · Tavneos · XELJANZ · ZTLido
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (76%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 8% for rheumatology in TX.

Equivalent to $33 per 100 Medicare services performed
Looking for a rheumatology in Red Oak?
Compare rheumatologys in the Red Oak area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
60
Per 100K population
29.4
County median income
$95,898
Nearest hospital
CRESCENT MEDICAL CENTER LANCASTER
4.6 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Patel is a mixed practice specialist, with above-average Medicare volume (top 3% in TX), and high industry engagement (speaking/promotional, top 8%).

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Patel experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Patel performed 173,200 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Patel receive payments from pharmaceutical companies?
Yes. Dr. Patel received a total of $76,139 from 38 companies across 912 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Patel's costs compare to other rheumatologys in Red Oak?
Dr. Patel's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Patel) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →